Authors: De Souza, M.V.N.
Source: Expert Opinion on Therapeutic Patents, v. 18, p. 1101-1105, 2008.
Publisher: Taylor & Francis Group
Abstract
Nowadays fixed-dose combinations and me-too drugs are important strategies in the fight against multi-drug resistant microorganisms and other kind of diseases and have been studied by several pharmaceutical companies. Considering this fact the present application from RIB-X Pharmaceuticals (WO2007133803) discloses a series of compounds based on oxazolidinone nucleus with or without triazole and macrolide groups to treat myco bacterial infections, in particular infections caused by multi-drug resistant microorganisms, such as Mycobacterium tuberculosis, and nontuberculosis mycobacteria, such as Mycobacterium avium complex–a combination of bacteria belonging to the genus Mycobacterium.Keywords: triazolesmacrolides, Mycobacterium tuberculosis, oxazolidinones Document Type: Review Article DOI: http://dx.doi.org/10.1517/13543776.18.9.1101 Publication date: 21 de Agosto de 2008
